Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward

Abstract

Background Knowledge of risk factors for drug-related hospitalizations (DRHs) is limited. Aim To examine the prevalence of DRHs and the relationships between DRHs and various variables in multimorbid patients admitted to an internal medicine ward. Methods Multimorbid patients ≥ 18 years, using minimum of four regular drugs from minimum two therapeutic classes, were included from the Internal Medicine ward, Oslo University Hospital, Norway, from August 2014 to March 2016. Clinical pharmacists prospectively conducted medicines reconciliations and reviews to reveal drug-related problems (DRPs). Blinded for identified DRPs, an interdisciplinary group retrospectively made comprehensive, clinical assessments of each patient case to classify hospitalizations as drug-related (DRH) or non-drug-related (non-DRH). Age, sex distribution, Charlson Comorbidity Index (CCI), renal function, aberrant genotype frequencies, body-mass index, number of drugs, proportion of patients which received assistance for drug administration from the home care service, and/or through multidose-dispensed drugs, and occurrence of specific DRP subgroups, were compared separately between patients with DRHs versus non-DRHs, followed by multiple logistic regression analysis. Results Hospitalizations were classified as drug-related in 155 of the 404 included patients (38%). Factors significantly associated with DRHs were occurrence of adverse effect DRPs (adjusted odds ratio (OR) 3.3, 95% confidence interval (CI) 1.4–8.0), adherence issues (OR 2.9, 1.1–7.2), home care (OR 1.9, 1.1–3.5), drug monitoring DRPs (OR 1.9, 1.2–3.0), and CCI score ≥6 (OR 0.33, 0.14–0.77). Frequencies of aberrant genotypes did not differ between the patient groups, but in 41 patients with DRHs (26.5%), gene-drug interactions influenced the assessments of DRHs. Conclusion DRHs are prevalent in multimorbid patients with adverse effect DRPs and adherence issues as the most important risk factors.

Effect of medicines management versus standard care on readmissions in multimorbid patients: a randomised controlled trial

“…The purpose of these baseline assessments was to assess the prevalence of DRPs and drug-related hospitalisations. 37 These medicines reviews included only drugs used before admission, not drugs initiated during transport, or following hospital admission. The pharmacists had access to the patient’s medical history and laboratory results up to and including admission time.…”

SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities

“…In a disease with a relatively low mortality and rudimentary understanding of its pathophysiology, potential risks for life-threatening side effects by unproven therapeutics must not be ignored in a pursuit of the desired benefits. The hazards of adverse effects are additionally aggravated by the typically advanced age of COVID-19 patients, who frequently present with various comorbidities and comedications ( 156 ). Properly designed animal experiments and clinical studies will gradually reveal the cons and pros of the experimental therapeutics.…”

Prevalence and predictors of multimorbidity among immigrant Asian Indian women residing in Sydney Australia: A cross-sectional study

“…13 The evidence suggests a higher risk of mortality among those with multimorbidity. 14,15 Similarly, the presence of multimorbidity increases the risk of hospitalizations, [16][17][18] and causes a decrease in physical functioning 19 and overall quality of life. 7,[20][21][22] In addition, multimorbidity increases polypharmacy [23][24][25] and psychological distress [25][26][27][28] resulting in substantial economic burden for health systems.…”